In CD8+ T cells, IL-33 enhances the antiviral functionality of effector CD8+ T cells during acute and latent infection as well as upon vaccination (McLaren et al., 2019; Kallert et al., 2017; Villarreal et al., 2014; Bonilla et al., 2012). Here, CD8A is linked to disease arising from reactivation of latent virus.